Neximmune Inc
F:737

Watchlist Manager
Neximmune Inc Logo
Neximmune Inc
F:737
Watchlist
Price: 3.3 EUR Market Closed
Market Cap: 86.1m EUR

Operating Margin
Neximmune Inc

0%
Current
0%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-26m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Neximmune Inc
F:737
86.1m EUR N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
406.5B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
28%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
No Stocks Found

Neximmune Inc
Glance View

Market Cap
86.1m EUR
Industry
Biotechnology

NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 74 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The firm provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.

Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-26m
/
Revenue
0
What is the Operating Margin of Neximmune Inc?

Based on Neximmune Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top